 NRx Pharmaceuticals Inc NASDAQ: NRXP has received the FDAs response to NRxs submission of updated manufacturing information for Zyesami aviptadil. The completion of this review, without the imposition of any clinical hold by the FDA, enables NRx to distribute Zyesami for clinical trials and other future purposes approved in future regulatory actions. 